[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351793-105":59,"doc-detail-351793-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","overcoming-adaptive-resistance-to-krasg12d-blockade-in-pancreatic-cancer-through-vertical-pathway-inhibition-research-findings","Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition - Research Findings","","Oncogenic KRAS mutations occur in over 90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D as the most frequent variant and KRASG12D inhibitors showing early clinical activity. Adaptive resistance reduces durable benefit, and the mechanisms in PDAC were unclear. Using KRASG12D-mutant PDAC models, adaptive RAS–MAPK signaling reactivated via RTKs. EGFR drove reactivation mainly in epithelial-state models, whereas FGFR signaling dominated in mesenchymal-state models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overcoming-adaptive-resistance-to-krasg12d-blockade-in-pancreatic-cancer-through-vertical-pathway-inhibition-research-findings/351793/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overcoming-adaptive-resistance-to-krasg12d-blockade-in-pancreatic-cancer-through-vertical-pathway-inhibition-research-findings/351793.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is KRASG12D inhibition limited by adaptive resistance in PDAC?","Question",{"text":112,"@type":113},"Although KRASG12D inhibitors initially show clinical promise, tumor cells can adapt by reactivating RAS–MAPK signaling through upstream receptor tyrosine kinases, reducing sustained efficacy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which receptor tyrosine kinases drive adaptive RAS–MAPK reactivation after KRASG12D blockade?",{"text":117,"@type":113},"EGFR is a primary driver in certain models with epithelial differentiation, while FGFR signaling primarily drives reactivation in models with mesenchymal differentiation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does adding a RAS(ON) multi-selective inhibitor affect treatment outcomes?",{"text":121,"@type":113},"A RAS(ON) multi-selective inhibitor that blocks both wild-type and mutant RAS abrogates KRASi-induced RAS–MAPK reactivation and produces more consistent antitumor activity across epithelial and mesenchymal models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351793,1790478932,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition  \nQingxiang Lin1,2, Alvin A. Morales-Giron1,2, Conrad Sander1,2, Jacquelyn M. Curtis1,2, Haley Barnes1,2, Parasvi S. Patel1,2, Ferran Fece de la Cruz1,2, Jakob M. Riedl1,2,3, Hiroyuki Matsubara1,2,  \nHajime Nakamura1,2, Andrew S. Liss1,2, and Ryan B. Corcoran1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Oncogenic KRAS mutations are present in >90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D being the most common. Mutant-selective KRASG12D inhibitors (KRASiG12D) have demonstrated promising initial clinical activity in KRASG12D-mutant PDAC. However, adaptive resistance to KRASi constrains efficacy in some tumor types, such as colorectal cancer, in which EGFR-mediated RAS–MAPK pathway reactivation can be targeted to improve response. Some studies have suggested a similar role for EGFR in PDAC, but the mechanisms of adaptive resistance to KRAS inhibition are unclear.\u003Cbr>Experimental Design: Mechanisms of adaptive resistance to KRASiG12D were investigated in a panel of KRASG12D-mutant PDAC models.\u003Cbr>Results: We observed receptor tyrosine kinase (RTK)–driven adaptive reactivation of RAS pathway signaling following KRASiG12D in PDAC models. EGFR was a primary driver of adaptive RAS–MAPK reactivation in some models but was limited to those\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | with epithelial differentiation. Conversely, adaptive RAS–MAPK reactivation in models with mesenchymal differentiation was primarily driven by FGFR signaling. In clinical PDAC specimens from The Cancer Genome Atlas, EGFR and ERBB3 expression was highly correlated with the expression of epithelial markers, whereas the expression of FGFR1 and mesenchymal markers was correlated. Notably, a RAS(ON) multi-selective inhibitor, which inhibits both wild-type and mutant RAS, abrogated RAS–MAPK reactivation in combination with KRASi in both epithelial and mesenchymal models and led to more consistent antitumor activity compared with combinations of KRASi and EGFR blockade.\u003Cbr>Conclusions: In PDAC, adaptive RAS–MAPK reactivation following KRASG12D inhibition can be mediated by different RTKs and influenced by cell state. Combinations of mutantselective KRASi and RAS(ON) multi-selective inhibitors may represent a promising universal strategy to surmount adaptive resistance in patients with PDAC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nPancreatic ductal adenocarcinoma (PDAC) is a leadin∼g cause of  \ncancer mortality, with a 5-year survival rate of only 12% (1) . Currently, it is the third leading cause of cancer-related deaths in the United States and is expected to rise to second by 2030 (2) . Most patients with PDAC are diagnosed with advanced, disseminated disease, precluding surgery for 80% of patients, and the limited treatment options, as well a","cbCaid8IHW6aGtWu","https://ap.wps.com/l/cbCaid8IHW6aGtWu","pdf",25322602,14,"English","# Introduction\n## KRAS alterations in PDAC\n## Rationale for targeting KRASG12D and overcoming resistance\n# Purpose, Experimental Design, Results, and Conclusions\n## RTK-driven adaptive RAS–MAPK reactivation after KRASG12D inhibition\n## Differing drivers by epithelial vs mesenchymal differentiation\n## RAS(ON) multi-selective inhibition as a strategy","[{\"question\":\"Why is KRASG12D inhibition limited by adaptive resistance in PDAC?\",\"answer\":\"Although KRASG12D inhibitors initially show clinical promise, tumor cells can adapt by reactivating RAS–MAPK signaling through upstream receptor tyrosine kinases, reducing sustained efficacy.\"},{\"question\":\"Which receptor tyrosine kinases drive adaptive RAS–MAPK reactivation after KRASG12D blockade?\",\"answer\":\"EGFR is a primary driver in certain models with epithelial differentiation, while FGFR signaling primarily drives reactivation in models with mesenchymal differentiation.\"},{\"question\":\"How does adding a RAS(ON) multi-selective inhibitor affect treatment outcomes?\",\"answer\":\"A RAS(ON) multi-selective inhibitor that blocks both wild-type and mutant RAS abrogates KRASi-induced RAS–MAPK reactivation and produces more consistent antitumor activity across epithelial and mesenchymal models.\"}]","Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition - Research Findings | PDF",1790095914,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edfed0a9e121b3950169bf8173fc3129.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21988d2e91366b268ccba6bc90af01d6.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8190781dd14f92547ca056f4123397ff.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fadd84630d85cb9760f59c6eea225af7.webp",980,1311]